Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials

被引:124
作者
Gibson, CM [1 ]
Karha, J [1 ]
Murphy, SA [1 ]
James, D [1 ]
Morrow, DA [1 ]
Cannon, CP [1 ]
Glugliano, RP [1 ]
Antman, EM [1 ]
Braunwald, E [1 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA
关键词
D O I
10.1016/S0735-1097(03)00506-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We hypothesized that early recurrent myocardial infarction (MI) following fibrinolytic administration would be assessed with higher mortality at both 30 days and 2 years. BACKGROUND Although early recurrent MI after fibrinolytic therapy has been associated with increased early mortality in the acute MI setting, its relation to long-term mortality has not been fully explored. METHODS Mortality data were ascertained in 20,101 patients enrolled in the Thrombolysis In Myocardial Infarction (TIMI) 4, 9, and 10B and Intravenous NPA for the Treatment of Infarcting Myocardium Early (InTIME-II) acute MI trials. RESULTS The frequency of symptomatic recurrent MI during the index hospitalization was 4.2% (836/20,101). Recurrent MI during the index hospital period was associated with increased 30-day mortality (16.4% [137/836] vs. 6.2% [1,188/19,260], p < 0.001). Likewise, recurrent MI was associated with a sustained increase in mortality up to two years, even after adjustments were made for covariates known to be associated with mortality and recurrent MI (hazard ratio 2.11, p < 0.001). However, this higher mortality at 2 years was due to an early divergence in mortality by 30 days and was not due to a significant increase in late mortality between 30 days and 2 years (4.38% [31/707] vs. 3.76% [685/18,206], p = NS). Percutaneous coronary intervention during the index hospitalization was associated with a lower rate of in-hospital recurrent MI (1.6% vs. 4.5%, p < 0.001) and lower two-year mortality (5.6% vs. 11.6%, p < 0.001). Performance of coronary artery bypass graft surgery was also associated with a lower recurrent rate of MI (0.7% vs. 4.3%, p < 0.001) and lower two-year mortality rate (7.95% vs. 10.6%, p = 0.0008). CONCLUSIONS Early recurrent MI is associated with increased mortality up to two years. However, most deaths occur early, and the risk of additional deaths between the index hospital period and two years was not significantly increased among patients with recurrent MI. Percutaneous coronary intervention during the index hospitalization was associated with a lower risk of recurrent MI and a lower risk of two-year mortality. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 25 条
  • [1] [Anonymous], 1990, LANCET, V336, P65
  • [2] [Anonymous], 1986, LANCET, V1, P397
  • [3] [Anonymous], 1989, NEW ENGL J MED, V320, P618
  • [4] HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL
    ANTMAN, EM
    [J]. CIRCULATION, 1994, 90 (04) : 1624 - 1630
  • [5] Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial
    Antman, EM
    [J]. CIRCULATION, 1996, 94 (05) : 911 - 921
  • [6] FREQUENCY, SIGNIFICANCE, AND COST OF RECURRENT ISCHEMIA AFTER THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION
    BARBAGELATA, A
    GRANGER, CB
    TOPOL, EJ
    WORLEY, SJ
    KEREIAKES, DJ
    GEORGE, BS
    OHMAN, EM
    LEIMBERGER, JD
    MARK, DB
    CALIFF, RM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (14) : 1007 - 1013
  • [7] Braunwald E, 2000, EUR HEART J, V21, P2005
  • [8] TNK tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction - Results of the TIMI 10B trial
    Cannon, CP
    Gibson, CM
    McCabe, CH
    Adgey, AAJ
    Schweiger, MJ
    Sequeira, RF
    Grollier, G
    Giugliano, RP
    Frey, M
    Mueller, HS
    Steingart, RM
    Weaver, WD
    Van de Werf, F
    Braunwald, E
    [J]. CIRCULATION, 1998, 98 (25) : 2805 - 2814
  • [9] COMPARISON OF FRONT-LOADED RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, ANISTREPLASE AND COMBINATION THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) 4 TRIAL
    CANNON, CP
    MCCABE, CH
    DIVER, DJ
    HERSON, S
    GREENE, RM
    SHAH, PK
    SEQUEIRA, RF
    LEYA, F
    KIRSHENBAUM, JM
    MAGORIEN, RD
    PALMERI, ST
    DAVIS, V
    GIBSON, CM
    POOLE, WK
    BRAUNWALD, E
    PULEO, P
    ABENDSCHEIN, D
    LOSCALZO, J
    CHAITMAN, BR
    ZARET, BL
    DANGOISSE, V
    FLAKER, GC
    GARRISON, TW
    SCHWEIGER, MJ
    MAHRER, PR
    SHOOK, TL
    ANDERSON, JL
    PALISAITIS, D
    COHN, PF
    LARAMEE, LA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (07) : 1602 - 1610
  • [10] Prospective validation of a composite end point in thrombolytic trials of acute myocardial infarction (TIMI 4 and 5)
    Cannon, CP
    Sharis, PJ
    Schweiger, MJ
    McCabe, CH
    Diver, DJ
    Shah, PK
    Sequeira, RF
    Greene, RM
    Perritt, RL
    Poole, WK
    Braunwald, E
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (06) : 696 - 699